News Conference News ESC 2022 Polypill Bests Usual Care in Patients With Recent MI: SECURE Michael O'Riordan August 26, 2022
News Daily News Steep Rise in PVAD Support for Protected PCI: Medicare Data Caitlin E. Cox August 19, 2022
News Daily News Even With Revascularization in ISCHEMIA, Skipping Meds Hurt Health Status Todd Neale August 19, 2022
News Daily News After COVID-19, Unvaccinated at Risk for Long-term CVD Complications Michael O'Riordan August 16, 2022
News Daily News Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution Michael O'Riordan August 11, 2022
News Daily News CABG Bests PCI in Patients With Good Physical, Mental Health: SYNTAXES Michael O'Riordan July 22, 2022
News Daily News Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy Todd Neale July 20, 2022
News Daily News INTEGRITTY Aims to Shine a Light on Research Bias, Including in LM Disease Michael O'Riordan July 12, 2022
News Daily News LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD Michael O'Riordan July 11, 2022
News Daily News ‘Redlining’ of Neighborhoods Left a Legacy of Poorer CV Health L.A. McKeown July 04, 2022
News Daily News EMERGE: Early Angiography Doesn’t Boost OHCA Survival After NSTEMI Caitlin E. Cox June 14, 2022
News Conference News TVT 2022 More Support for Single Antiplatelet Therapy After TAVI Michael O'Riordan June 10, 2022
News Daily News Following Takotsubo, Men Have Worse Outcomes, Are More Likely to Die Than Women Yael L. Maxwell June 03, 2022
News Conference News EAS 2022 Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively Michael O'Riordan May 27, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EuroPCR 2022 CCTA Increases Contrast Volume in Patients With Prior CABG: GREECE Trial Yael L. Maxwell May 24, 2022
News Conference News EAS 2022 Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level Michael O'Riordan May 24, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022